Heather Rees - Atossa Genetics VP Accounting
| ATOS Stock | USD 0.66 0.04 6.45% |
Insider
Heather Rees is VP Accounting of Atossa Genetics
| Age | 52 |
| Address | 107 Spring Street, Seattle, WA, United States, 98104 |
| Phone | 206 588 0256 |
| Web | https://www.atossatherapeutics.com |
Heather Rees Latest Insider Activity
Tracking and analyzing the buying and selling activities of Heather Rees against Atossa Genetics stock is an integral part of due diligence when investing in Atossa Genetics. Heather Rees insider activity provides valuable insight into whether Atossa Genetics is net buyers or sellers over its current business cycle. Note, Atossa Genetics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Atossa Genetics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Heather Rees over a year ago Atossa Genetics exotic insider transaction detected |
Atossa Genetics Management Efficiency
The company has return on total asset (ROA) of (0.2987) % which means that it has lost $0.2987 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4889) %, meaning that it created substantial loss on money invested by shareholders. Atossa Genetics' management efficiency ratios could be used to measure how well Atossa Genetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2026. Return On Capital Employed is likely to drop to -0.37 in 2026. At this time, Atossa Genetics' Total Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 2.4 M in 2026, whereas Intangible Assets are likely to drop slightly above 11.4 K in 2026.Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert MD | Clene Inc | 67 | |
| Timothy Moore | Instil Bio | 63 | |
| Snehal Patel | Greenwich Lifesciences | 63 | |
| Mark Dudley | Instil Bio | N/A | |
| Elizabeth Nguyen | Surrozen | N/A | |
| Charles Williams | Surrozen | 46 | |
| MS JD | Surrozen | 62 | |
| DSc MSE | Immix Biopharma | 75 | |
| Eric Rothe | Greenwich Lifesciences | 51 | |
| MBA MD | Surrozen | 56 | |
| Grey Wilkinson | Oncolytics Biotech | N/A | |
| Mark Mortenson | Clene Inc | 66 | |
| Bronson Crouch | Instil Bio | 53 | |
| Calvin MD | Surrozen | N/A | |
| Gabriel BA | Immix Biopharma | 40 | |
| Frank MD | Greenwich Lifesciences | 76 | |
| MBA MD | Immix Biopharma | 49 | |
| Andrew CPA | Cognition Therapeutics | 64 | |
| Roeland Nusse | Surrozen | 76 | |
| Nandan BS | Immix Biopharma | 63 | |
| WenChen MD | Surrozen | 60 | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 |
Atossa Genetics Leadership Team
Elected by the shareholders, the Atossa Genetics' board of directors comprises two types of representatives: Atossa Genetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atossa. The board's role is to monitor Atossa Genetics' management team and ensure that shareholders' interests are well served. Atossa Genetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atossa Genetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Heather CPA, Senior Officer | ||
| Michael Parks, Vice Relations | ||
| Mark CPA, Chief Officer | ||
| Heather Rees, VP Accounting | ||
| FCAP MD, CEO Chairman | ||
| RAC MSPH, VP of Regulatory Affairs and Quality | ||
| Delly PHR, Senior Operations | ||
| Eric Zanten, Vice Relations | ||
| Richard MD, Interim Officer | ||
| CPA Esq, Gen CFO |
Atossa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Atossa Genetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 28.22 M | ||||
| Shares Outstanding | 129.17 M | ||||
| Shares Owned By Insiders | 0.07 % | ||||
| Shares Owned By Institutions | 19.45 % | ||||
| Number Of Shares Shorted | 2.28 M | ||||
| Price To Earning | (0.62) X | ||||
| Price To Book | 1.61 X | ||||
| EBITDA | (27.6 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.